华芢生物上市首日收跌29.32%

Core Viewpoint - Huazhang Biopharmaceutical (02396.HK) experienced a significant decline of 29.32% on its first day of trading on the Hong Kong Stock Exchange, closing at HKD 27 per share [1] Company Overview - Established in 2012, Huazhang Biopharmaceutical is a biopharmaceutical company headquartered in China [1] - The company focuses on developing various therapies, particularly protein drugs targeting medical needs and market opportunities [1] - Huazhang's primary focus is on discovering, developing, and commercializing therapies for wound healing, with a current emphasis on platelet-derived growth factor (PDGF) drugs [1]